Plasma MCP-1 and changes on cognitive function in community-dwelling older adults

Area of Science:

• Neuroscience
• Immunology
• Gerontology

Background:

• Monocyte Chemoattractant Protein-1 (MCP-1) is a glial-derived chemokine implicated in neuroinflammation.
• MCP-1 may influence memory function in aging populations.
• Understanding MCP-1's role in cognitive decline is crucial for developing targeted interventions.

Purpose of the Study:

• To investigate the association between plasma MCP-1 levels and cognitive changes in older adults.
• To explore the combined effect of MCP-1 and beta-amyloid (Aβ42/40) on cognitive trajectories.
• To determine if MCP-1 predicts declines in overall and domain-specific cognitive functions.

Main Methods:

• Analysis of 1097 participants from the Multidomain Alzheimer Preventive Trial (MAPT).
• Measurement of plasma MCP-1 and Aβ42/40 levels at baseline.
• Assessment of cognitive function annually over 4 years using composite scores, MMSE, CDR, and FCSRT.

Main Results:

• Elevated plasma MCP-1 levels were associated with worsening episodic memory, particularly delayed recall.
• Higher MCP-1 levels correlated with declines in overall cognitive function (CCS and CDR).
• The association between MCP-1 and cognitive decline was more pronounced in individuals with lower Aβ42/40 levels, suggesting an interaction.

Conclusions:

• Baseline plasma MCP-1 levels predict longitudinal declines in cognitive and episodic memory performance in older adults.
• The interaction between MCP-1 and Aβ42/40 warrants further investigation to understand their combined impact on cognitive decline.
• MCP-1's impact on cognitive decline is amplified in the presence of amyloid pathology, as indicated by plasma Aβ42/40.